Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study
Michael Wang(St. Joseph Health System), Kristie A. Blum(Emory University), Stephen E. Spurgeon(Oregon Health & Science University), Peter Johnson(Cancer Research UK), John Radford(Manchester Academic Health Science Centre), Stephan Stilgenbauer(Universität Ulm), Peter Martin(Northwestern University), Martin Dreyling(LMU Klinikum), Simon Rule(AstraZeneca (United Kingdom)), Ranjana H. Advani(Stanford Medicine), Brad S. Kahl(UW Health University Hospital), Jacqueline C. Barrientos(Mount Sinai Medical Center), Ewa Chmielowska(Centrum Onkologii), Jorge Romaguera(The University of Texas MD Anderson Cancer Center), André Goy(Hackensack University Medical Center), Linda Baher(Pharmacyclics (United States)), Liang Zhang(Mayo Clinic), Michael E. Williams(University of Virginia), Wojciech Jurczak(Jagiellonian University), W Wiktor-Jędrzejczak(Medical University of Warsaw), Rebecca Auer(St Bartholomew's Hospital), Mei Cheng(Pharmacyclics (United States)), Darrin M. Beaupre(Pharmacyclics (United States))
Cited by 16
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k